SEC 13F Intelligence

Managers / Q4 2019 · view latest →

Endurant Capital Management LP

CIK 0001633055 · 66 BOVET ROAD, SUITE 353, SAN MATEO, CA, 94402 · 650-539-5905

Reported Value
$317M
Q4 2019
Positions
54
Filings on Record
24
2019–present window
Filed
Feb 14, 2020
original filing

Summary

Endurant Capital Management LP reported $317M in U.S.-listed holdings across 54 positions for Q4 2019.

Its largest position, BMY, represents 8.1% of the portfolio.

Compared with Q3 2019, the fund opened 23 new positions and exited 19.

Portfolio Metrics

Turnover
+42.2%
vs prior filed quarter
Top-10 Concentration
+57.2%
share of reported value
Largest Position
+8.1%
Bristol Myers Squibb
New / Exited
23 / 19
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $189MQ4 ’18Q1 ’19: $253MQ2 ’19: $254MQ3 ’19: $279MQ3 ’19Q4 ’19: $317MQ1 ’20: $221MQ2 ’20: $1.8BQ2 ’20Q3 ’20: $338MQ4 ’20: $277MQ1 ’21: $384MQ1 ’21Q2 ’21: $364MQ3 ’21: $439MQ4 ’21: $414MQ4 ’21Q1 ’22: $380MQ2 ’22: $285MQ3 ’22: $307MQ3 ’22Q4 ’22: $246MQ1 ’23: $195MQ2 ’23: $115MQ2 ’23Q3 ’23: $111MQ4 ’23: $17MQ1 ’24: $0Q1 ’24filingsflow.com

Portfolio Composition

By security type
Common Stock: 80.6%Other: 13.1%US DOMESTIC: 3.6%ETP: 1.7%ADR: 1.0%
  • Common Stock · 80.6% · $256M
  • Other · 13.1% · $42M
  • US DOMESTIC · 3.6% · $11M
  • ETP · 1.7% · $5M
  • ADR · 1.0% · $3M

Quarter-over-Quarter Changes full breakdown →

vs Q3 2019 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
REGNREGENERON PHARMACEUTICALSNEW+27.4K27.4K+$10M$10M
SIBNSI BONE INCNEW+470.4K470.4K+$10M$10M
IQVIQVIA HLDGS INCNEW+49.8K49.8K+$8M$8M
HRCHILL ROM HLDGS INCNEW+65.8K65.8K+$7M$7M
IRTCIRHYTHM TECHNOLOGIES INCNEW+89.6K89.6K+$6M$6M
EVHEVOLENT HEALTH INCNEW+597.3K597.3K+$5M$5M
SRPTSAREPTA THERAPEUTICS INCNEW+39.8K39.8K+$5M$5M
AL21ALLSCRIPTS HEALTHCARE SOLUTNNEW+448.0K448.0K+$4M$4M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2019

48 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1BMYBRISTOL MYERS SQUIBB COhistory →COM8.12%$26M401.4K
2ELVANTHEM INChistory →COM7.81%$25M82.0K
3ZBHZIMMER BIOMET HLDGS INChistory →COM6.42%$20M136.2K
4OXFORD IMMUNOTEC GLOBAL PLCORD SHS6.37%$20M1.22M
5ABGAMERISOURCEBERGEN CORPhistory →COM5.86%$19M218.8K
6LABORATORY CORP AMER HLDGSCOM NEW5.76%$18M108.0K
7CICIGNA CORP NEWhistory →COM5.20%$17M80.7K
8BDXBECTON DICKINSON & COhistory →COM4.89%$16M57.1K
9EVHEVOLENT HEALTH INCNOTE 2.000%12/0 · CL A4.84%$15M608.4K
10EHCENCOMPASS HEALTH CORPhistory →COM3.56%$11M163.1K
11REGNREGENERON PHARMACEUTICALShistory →COM3.24%$10M27.4K
12SIBNSI BONE INChistory →COM3.19%$10M470.4K
13ABBVABBVIE INChistory →COM2.75%$9M98.6K
14IQVIQVIA HLDGS INChistory →COM2.42%$8M49.8K
15HRCHILL ROM HLDGS INChistory →COM2.35%$7M65.8K
16PRAHPRA HEALTH SCIENCES INChistory →COM2.07%$7M59.0K
17IRTCIRHYTHM TECHNOLOGIES INChistory →COM1.92%$6M89.6K
18ZTSZOETIS INChistory →CL A1.68%$5M40.2K
19SRPTSAREPTA THERAPEUTICS INChistory →COM1.62%$5M39.8K
20IOVAIOVANCE BIOTHERAPEUTICS INChistory →COM1.47%$5M168.5K
21AL21ALLSCRIPTS HEALTHCARE SOLUTNhistory →COM1.39%$4M448.0K
22ACRSACLARIS THERAPEUTICS INChistory →COM1.22%$4M2.06M
23PRNBPRINCIPIA BIOPHARMA INChistory →COM1.14%$4M66.2K
24FLBFLUIDIGM CORP DELhistory →COM1.13%$4M1.03M
25XRAYDENTSPLY SIRONA INChistory →COM1.01%$3M56.7K
26RCMEURR1 RCM INChistory →COM1.01%$3M246.0K
27GW PHARMACEUTICALS PLCADS0.98%$3M29.7K
28BAXBAXTER INTL INCCOM0.90%$3M34.2K
29FATEFATE THERAPEUTICS INCCOM0.83%$3M135.0K
30ADVMCHFADVERUM BIOTECHNOLOGIES INCCOM0.78%$2M214.8K
31SILKUSDSILK ROAD MEDICAL INCCOM0.65%$2M51.3K
32CNMDCONMED CORPCOM0.63%$2M17.9K
33AHCOADAPTHEALTH CORPCOM CL A0.58%$2M167.9K
34PROTHENA CORP PLCSHS0.55%$2M110.1K
35SENSEONICS HLDGS INCNOTE 5.250% 2/00.47%$1M1.5K
36MCKMCKESSON CORPCOM0.45%$1M10.4K
37LQDALIQUIDIA TECHNOLOGIES INCCOM0.43%$1M318.0K
38MGNXMACROGENICS INCCOM0.42%$1M122.9K
39TNDMTANDEM DIABETES CARE INCCOM NEW0.40%$1M21.4K
40AXSMAXSOME THERAPEUTICS INCCOM0.36%$1M11.2K
41TRLDAVITA INCCOM0.28%$901,00012.0K
42NUCANA PLCSPONSORED ADR0.21%$666,000109.2K
43APLSUSDAPELLIS PHARMACEUTICALS INCCOM0.19%$593,00019.4K
44SDCCQSMILEDIRECTCLUB INCCL A COM0.16%$517,00059.2K
45GNCAQGENOCEA BIOSCIENCES INCCOM NEW0.16%$493,000238.2K
46SUTRO BIOPHARMA INCCOM0.11%$359,00032.7K
47WRIGHT MED GROUP N VORD SHS0.11%$356,00011.7K
48DRNAUSDDICERNA PHARMACEUTICALS INCCOM0.10%$303,00013.8K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2024$01May 7, 202413F-HRchanges · EDGAR ↗
Q4 2023$17M25Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$111M43Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$115M34Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$195M50May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$246M55Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$307M49Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$285M50Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$380M63May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$414M68Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$439M53Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$364M57Aug 27, 2021RESTATEMENTchanges · EDGAR ↗
Q1 2021$384M61May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$277M52Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$338M60Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$1.8B56Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$221M51May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$317M54Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$279M49Nov 25, 2019RESTATEMENTchanges · EDGAR ↗
Q2 2019$254M50Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$253M70May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$189M48Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.